Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (224)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (637)
  2. Solid Tumor Oncology Division (637)
  3. Thoracic Oncology (637)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (21)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (85)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (119)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (637)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A clinical utility study of plasma DNA next generation sequencing guided treatment of uncommon drivers in advanced non-small-cell lung cancers
    Meeting Abstract

    Tu, H.; Xu, C.; Tong-Li, C.; Offin, M.; Razavi, P.; Schapira, E.; Namakydoust, A.; Lee, A.; Pavlakis, N.; Clarke, S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Entrectinib in patients with ROS1-positive NSCLC or NTRK fusion-positive solid tumors with CNS metastases
    Meeting Abstract

    Paz-Ares, L.; Dziadziuszko, R.; Drilon, A.; John, T.; Krebs, M.; Demetri, G.; Shaw, A.; Siena, S.; Wolf, J.; Farago, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Activity of larotrectinib in TRK fusion lung cancer
    Meeting Abstract

    Farago, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Ku, N.; Cox, M.; Nanda, S.; Childs, B.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • MSK-IMPACT, a hospital based genetic screening using FDA-approved NGS system
    Meeting Abstract

    Drilon, A.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Drilon, A.; Oxnard, G.; Wirth, L.; Besse, B.; Gautschi, O.; Tan, S. W. D.; Loong, H.; Bauer, T.; Kim, Y. J.; Horiike, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
    Meeting Abstract

    Wirth, L.; Sherman, E.; Drilon, A.; Solomon, B.; Robinson, B.; Lorch, J.; McCoach, C.; Patel, J.; Leboulleux, S.; Worden, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
    Meeting Abstract

    Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
    Meeting Abstract

    Liu, S. V.; Duruisseaux, M.; Tolba, K.; Branden, E.; Goto, Y.; Weinberg, B. A.; Renouf, D. J.; Doebele, R. C.; Heining, C.; Schlenk, R. F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    De Braud, F. G. M.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B. P.; Huang, X.; Ye, C.; Doebele, R. C.
    Annals of Oncology (2019)

    Fulltext@MSK | Save